Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · July 13, 2023

Sugemalimab or Placebo Plus Chemotherapy as First-Line Treatment for Metastatic NSCLC

Nature Cancer


Additional Info

Nature Cancer
Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC
Nat Cancer 2023 Jun 01;4(6)860-871, C Zhou, Z Wang, M Sun, L Cao, Z Ma, R Wu, Y Yu, W Yao, S Sun, J Chen, W Zhuang, J Cui, X Chen, Y Lu, H Shen, C Hu, J Liu, Y Liu, M Wang, X Li, P Sun, Y Shu, J Zhou, J Li, K Gu, C Wang, H Zhao, Y Zhang, C Liu, J Wang, R Chen, M Qin, H Wang, J Yang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading